Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + chemotherapy (Roche)
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
H + CT is a clinical shorthand notation for the combination of trastuzumab (H) and chemotherapy (CT), which is the standard-of-care first-line treatment for patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. Trastuzumab is a humanized IgG1 monoclonal antibody that binds to the extracellular domain of the HER2 receptor, thereby inhibiting downstream signaling pathways and inducing antibody-dependent cellular cytotoxicity (ADCC). The chemotherapy component typically consists of a platinum agent (e.g., cisplatin) and a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), which exert broad cytotoxic effects by interfering with DNA replication and repair. This regimen was established as a standard following the results of the Phase 3 ToGA trial.
- Brand names
- Herceptin
- Other names
- trastuzumab plus chemotherapytrastuzumab-based chemotherapy
02
Targets
TS (Thymidylate synthase)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + chemotherapy (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + chemotherapy (Roche).